Humacyte Announces First Symvess鈩� Sale to Military Treatment Facility
Humacyte (Nasdaq: HUMA) announced its first sale of Symvess to a U.S. Military Treatment Facility, following its recent Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency. The facility serves approximately 200,000 active-duty service personnel, retirees, and family members.
Symvess, an acellular tissue engineered vessel approved by the FDA in December 2024 for extremity vascular trauma, is now available to approximately 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals through the ECAT system, which provides DOD and other federal agencies access to medical products.
Humacyte (Nasdaq: HUMA) ha annunciato la sua prima vendita di Symvess a una Struttura Sanitaria Militare degli Stati Uniti, a seguito della recente approvazione per l'inserimento nel Catalogo Elettronico (ECAT) da parte della U.S. Defense Logistics Agency. La struttura assiste circa 200.000 membri del personale in servizio attivo, pensionati e familiari.
Symvess, un vaso ingegnerizzato a tessuto acellulare approvato dalla FDA nel dicembre 2024 per il trattamento di traumi vascolari agli arti, 猫 ora disponibile per circa 35 Strutture Sanitarie Militari e 160 ospedali del Dipartimento per gli Affari dei Veterani degli Stati Uniti tramite il sistema ECAT, che consente al DOD e ad altre agenzie federali di accedere a prodotti medici.
Humacyte (Nasdaq: HUMA) anunci贸 su primera venta de Symvess a una Instalaci贸n de Tratamiento Militar de EE. UU., tras su reciente aprobaci贸n para su inclusi贸n en el Cat谩logo Electr贸nico (ECAT) por parte de la Agencia de Log铆stica de Defensa de EE. UU. La instalaci贸n atiende aproximadamente a 200,000 miembros del personal en servicio activo, retirados y familiares.
Symvess, un vaso tejido acellular aprobado por la FDA en diciembre de 2024 para trauma vascular en extremidades, ahora est谩 disponible para aproximadamente 35 Instalaciones de Tratamiento Militar y 160 hospitales del Departamento de Asuntos de Veteranos de EE. UU. a trav茅s del sistema ECAT, que proporciona acceso a productos m茅dicos al DOD y otras agencias federales.
Humacyte (雮橃姢雼�: HUMA)電� 斓滉芳 氙戈淡 甑癌氍茧觳�(U.S. Defense Logistics Agency)鞚� 鞝勳瀽 旃错儓搿滉犯(ECAT) 霌膘灛 鞀轨澑鞚� 氚涭潃 頉�, 氙戈淡 甑办偓 旃橂 鞁滌劋鞐� Symvess 觳� 韺愲Г毳� 氚滍憸頄堨姷雼堧嫟. 頃措嫻 鞁滌劋鞚� 鞎� 20毵� 氇呾潣 順勳棴 甑办澑, 韲挫棴 甑办澑 氚� 臧�臁膘潉 雽�靸侅溂搿� 靹滊箘鞀るゼ 鞝滉车頃╇媹雼�.
Symvess電� 2024雲� 12鞗� FDA 鞀轨澑鞚� 氚涭潃 氍挫劯韽� 臁办 瓿淀暀 順堦磤鞙茧, 靷 順堦磤 鞕胳儊 旃橂鞖╈澊氅� 順勳灛 鞎� 35臧� 甑办偓 旃橂 鞁滌劋瓿� 160臧� 氙� 氤错泩觳� 氤戩洂鞐愳劀 ECAT 鞁滌姢韰滌潉 韱淀暣 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟. ECAT 鞁滌姢韰滌潃 甑癌攵� 氚� 旮绊儉 鞐半癌 旮瓣磤鞐� 鞚橂 鞝滍拡 鞝戧芳鞚� 鞝滉车頃╇媹雼�.
Humacyte (Nasdaq : HUMA) a annonc茅 sa premi猫re vente de Symvess 脿 un 茅tablissement de soins militaires am茅ricain, suite 脿 l'approbation r茅cente de son inscription au catalogue 茅lectronique (ECAT) de l'Agence de logistique de la D茅fense des 脡tats-Unis. L'茅tablissement dessert environ 200 000 personnels en service actif, retrait茅s et leurs familles.
Symvess, un vaisseau tissulaire acellulaire approuv茅 par la FDA en d茅cembre 2024 pour les traumatismes vasculaires des extr茅mit茅s, est d茅sormais disponible dans environ 35 茅tablissements de soins militaires et 160 h么pitaux du D茅partement des anciens combattants des 脡tats-Unis via le syst猫me ECAT, qui offre au DOD et 脿 d'autres agences f茅d茅rales un acc猫s aux produits m茅dicaux.
Humacyte (Nasdaq: HUMA) gab den ersten Verkauf von Symvess an eine Milit盲rische Behandlungseinrichtung in den USA bekannt, nachdem die k眉rzliche Zulassung zur Aufnahme in den Elektronischen Katalog (ECAT) durch die U.S. Defense Logistics Agency erteilt wurde. Die Einrichtung betreut etwa 200.000 aktive Dienstangeh枚rige, Veteranen und deren Familien.
Symvess, ein zellfreies, gewebetechnisch hergestelltes Gef盲脽, das im Dezember 2024 von der FDA f眉r Gef盲脽traumata an Extremit盲ten zugelassen wurde, ist nun 眉ber das ECAT-System, das dem Verteidigungsministerium und anderen Bundesbeh枚rden den Zugang zu medizinischen Produkten erm枚glicht, in etwa 35 Milit盲rischen Behandlungseinrichtungen und 160 Krankenh盲usern des US Veteranenministeriums 惫别谤蹿眉驳产补谤.
- First commercial sale of Symvess to a major U.S. Military Treatment Facility
- Access to large military healthcare market through ECAT listing approval
- Product now available to approximately 195 combined DOD and VA facilities
- Recent FDA approval enables commercial sales for extremity vascular trauma
- Limited to single FDA-approved indication (extremity vascular trauma)
- Other potential uses still require regulatory approval
Insights
Humacyte's first Symvess sale marks commercial milestone, opening significant military/VA market following FDA approval and ECAT listing.
This announcement represents a significant commercial milestone for Humacyte, marking the company's first sale of Symvess following its FDA approval in December 2024. This initial penetration into the defense healthcare system is strategically important as it validates both market acceptance and the company's ability to commercialize its bioengineered tissue technology.
The ECAT listing approval is particularly noteworthy as it creates an established procurement pathway to approximately 35 Military Treatment Facilities and 160 VA hospitals - representing substantial market potential. With a large military facility serving 200,000 potential patients making the first purchase, this suggests confidence in the technology from sophisticated medical practitioners.
Symvess, an acellular tissue engineered vessel, addresses the critical extremity vascular trauma indication, which is especially relevant in military medicine where traumatic injuries are unfortunately common. The company's ability to manufacture universally implantable bioengineered human tissue at commercial scale could provide significant advantages over traditional grafting options, potentially reducing complications and improving outcomes.
This initial sale represents the beginning of Humacyte's commercial journey rather than its culmination. Military adoption often serves as a rigorous proving ground for medical innovations, potentially accelerating broader market acceptance if outcomes prove favorable. Investors should monitor the pace of additional facility adoptions following this first sale as an indicator of commercial trajectory.
Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency
Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities
DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today the first sale of Symvess to a U.S. Military Treatment Facility. The facility is a state-of-the-art medical complex located on a major U.S. military base that provides health care to approximately 200,000 active-duty service personnel, retirees, and their family members.
This sale follows the recent ECAT listing approval from the U.S. Defense Logistics Agency. ECAT is an internet system that provides the Department of Defense (DOD) and other federal agencies with access to manufacturers鈥� and distributors鈥� products. The ECAT approval makes Symvess available to healthcare professionals treating military service members, veterans, and other patients receiving care at approximately 35 Military Treatment Facilities and approximately 160 U.S. Department of Veterans Affairs hospitals.
Symvess (acellular tissue engineered vessel-tyod) was approved in the extremity vascular trauma indication by the Food and Drug Administration (FDA) in December 2024.
鈥淲e are excited to see the first purchase and use of Symvess by a military treatment facility,鈥� said Dr. Laura Niklason, President and CEO of Humacyte, Inc.聽鈥淲e have great interest in improving the medical options available to healthcare professionals treating military personnel and their families, and look forward to advancing our discussions with additional DOD hospitals.鈥�
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for use or sale by the FDA or any other regulatory agency.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing an innovative biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues designed to treat a wide range of diseases, injuries, and chronic conditions. Humacyte鈥檚 Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte鈥檚 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA鈥檚 Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte鈥檚 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit .
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渙ngoing鈥� or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize our ATEV in the United States under the brand name Symvess in vascular trauma repair; the anticipated characteristics and performance of our ATEVs; and the anticipated benefits of the ATEV relative to existing alternatives. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header 鈥淩isk Factors鈥� in our Annual Report on Form 10-K for the year ended December 31, 2024 and the Form 10-Q for the quarter ended March 31, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte鈥檚 control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
FAQ
What is Humacyte's Symvess and when was it FDA approved?
How many facilities can now access Humacyte's Symvess through ECAT?
What is the significance of HUMA's first military facility sale?
What is ECAT and how does it benefit Humacyte?
What patient population can access Symvess at the first military facility?
